Medivolve Announces Investment Into Marvel Diagnostics and Its Non-Invasive Exhaled Breath Diagnostic Technology - Seite 2

The BlowFISH collector will be compatible with existing and emerging POC diagnostic test systems, such as an rtPCR-based test. It is a simple matter of extracting the exhaled breath condensate from the collection zone and shipping it off for diagnostic testing.

This technology is being developed as an alternate solution to the standard diagnostic testing techniques for upper respiratory infections, which are conducted through deep nasal swabbing. This deep nasal swabbing is invasive, uncomfortable and requires trained personnel to reduce error, avoid tissue damage and prevent secondary infection, creating concerns over patient compliance. The non-invasive nature of the collector is particularly useful for children and adults who require multiple sampling.

The system also provides some additional unique advantages

1. Maximizes the collection of virus shed in the exhalate;
2. Samples directly from deep within the lungs;
3. Enables rapid (~10 minute) diagnosis; and
4. Forms the base technology for a line of sentinel systems for environmental testing.

“By combining our groundbreaking innovations in fluid flow, heat transfer, mass transfer and surface science, we are able to capture aerosolized virus particles in exhaled breath at a very high rate using our BlowFISH technology. Adding fast detection to the collection device will provide a low-cost, high accuracy collection/detection system that can provide not only positive/negative results, it can also be used to measure the level of infectousness and identify super spreaders,” Dr. Pirouz Kovehpour, UCLA Professor and Marvel Diagnostics co-Founder.

COVID-19 Research Disclaimer: Medivolve cautions that this research is still early stage research and development and is not making any express or implied claims that it has or will have the ability to detect the SARS-CoV-2 virus at this time. Further, Medivolve cautions that it is not making any express or implied claims that the device(s) or technology will have successful clinical study results or be in a position to obtain FDA approvals required to commercialize the technology.

About the Agreement
The share purchase agreement allows Medivolve to purchase up to 40% of Marvel Diagnositics for an agreegate purchase price of up US$1 million. Medivolve will make an initial investment of US$165,000 within 30 days to acquire approximately 6.6% of Marvel Diagnostics. Medivolve will make a second investment of US$165,000 within 60 days to acquire an additional 6.6% of Marvel Diagnostics. Following the two initial investments, Medivolve shall have the right to purchase an additional 26.8% of Marvel based on a series of milestones that include: